Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

EMPAGLIFLOZIN

All products: general benefit

Other products in the same Health Canada class (A10B, A10BK) — coverage varies; not interchangeable

  • Canagliflozin (Invokana): general benefit
  • Dapagliflozin (Forxiga): general benefit
  • Dapagliflozin + metformin (Xigduo): general benefit
  • Empagliflozin + metformin (Synjardy): general benefit
  • Gliclazide (Diamicron MR): general benefit, Not a benefit
  • Glyburide (Apo-Glyburide): general benefit, Not a benefit

12 more in the class list below

Jardiance · DIN 02443945 · 25mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Jardiance · DIN 02443945 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2016-05-31 Health Canada: Marketed since 2015-08-11 · brand JARDIANCE · ATC A10BK03 EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 25 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Check this DIN again · Health Canada product record

Jardiance: Formulary list price $2.8868/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.8868 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92872 · Verify on the e-Formulary ↗ (DIN 02443945)

Source record
DIN 02443945: Jardiance Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002058; group id 743; item number 1816; lccId None; manufacturer id BOE Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $2.8868; ministry $2.8868 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443945 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92872 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered

Matched class: 68:20:02 Oral Anti-Diabetic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN, SITAGLIPTIN & METFORMIN Some products covered without a code (check the product listing): GLICLAZIDE, GLYBURIDE, METFORMIN HCL 68:20:02 Oral Anti-Diabetic Agents

CANAGLIFLOZIN

· 8 products · General benefit · strengths: 100mg, 300mg · Tab

DAPAGLIFLOZIN

· 22 products · General benefit · strengths: 5mg, 10mg · Tab

DAPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab

EMPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab

GLICLAZIDE

· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab

GLYBURIDE

· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab

LINAGLIPTIN

· 1 products · General benefit · strengths: 5mg · Tab

LINAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

METFORMIN HCL

· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab

SAXAGLIPTIN

· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab

SAXAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

SITAGLIPTIN

· 48 products · General benefit · strengths: 25mg, 50mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:02 and 6 more
Full class listing Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: heart failure
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: DAPAGLIFLOZIN DAPAGLIFLOZIN · General benefit Heart Failure FORXIGA is indicated in adults, as an adjunct to standard of care therapy, for the treatment of heart failure to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure and urgent heart failure visit. PM: https://pdf.hres.ca/dpd_pm/00078350.PDF; date Dec 10, 2014; DIN 02435462; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Type 2 diabetes mellitus (T2DM) Monotherapy: JARDIANCE (empagliflozin) is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with T2DM for whom metformin is inappropriate due to contraindications or intolerance. Add-on combination: JARDIANCE is indicated in adult patients with T2DM to improve glycemic control in combination with: • metformin • metformin and a sulfonylurea • pioglitazone (alone or with metformin) • linagliptin and metformin • basal or prandial insulin (alone or with metformin) when metformin alone or the existing therapy listed above, along with diet and exercise, do not provide adequate glycemic control. Add-on combination in patients with established cardiovascular disease: JARDIANCE is indicated as an adjunct to diet, exercise and standard care therapy to reduce the incidence of cardiovascular death in patients with T2DM and established cardiovascular disease. Important Limitations of Use: Use of JARDIANCE with insulin mix (regular or analogue mix) has not been studied. Therefore, JARDIANCE should not be used with insulin mix. Heart Failure (HF) JARDIANCE … https://pdf.hres.ca/dpd_pm/00081256.PDF PM date: JUL 23, 2015 Source product: JARDIANCE; DIN 02443937; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.